Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott Aims For Mid-Year Products Reintroduction Following Consent Decree

This article was originally published in The Gray Sheet

Executive Summary

Abbott Laboratories hopes to reintroduce a number of its diagnostics products to the market in the second half of 2001 following a November 1999 consent decree issued by FDA.

You may also be interested in...



Abbott HIV P24 Antigen Test Recall Limited To About 350 Kits

A firm-initiated recall of Abbott's HIVAG-1 monoclonal HIV p24 antigen test kits initiated Feb. 13 stems from underfilled antibody vials and is limited to a single lot of about 350 test kits.

Abbott HIV P24 Antigen Test Recall Limited To About 350 Kits

A firm-initiated recall of Abbott's HIVAG-1 monoclonal HIV p24 antigen test kits initiated Feb. 13 stems from underfilled antibody vials and is limited to a single lot of about 350 test kits.

Abbott's AFP, CA 125 Cancer Tests Unaffected By Consent Decree

Abbott Laboratories' AFP and CA 125 diagnostic cancer tests are among the diagnostic products deemed "medically necessary" by FDA and will continue to be made available under the company's Nov. 2 consent decree with the agency.

Related Content

UsernamePublicRestriction

Register

MT014367

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel